Becton Dickinson & Co (NYSE:BDX) executive Roland Goette, EVP and President EMEA, has recently sold a total of 3,300 shares of the company's common stock, resulting in proceeds exceeding $780,000. This transaction was reported in a filing with the Securities and Exchange Commission dated May 16, 2024.
The shares were sold in multiple transactions at prices ranging from $235.29 to $237.46. The specific breakdown of the sales includes 800 shares at an average price of $235.29, 1,400 shares at an average price of $236.99, and 1,100 shares at an average price of $237.46. Following these transactions, Goette's direct holdings in Becton Dickinson have decreased to 11,308 shares.
It is important to note that the sale prices reported are weighted averages, and the actual sales occurred at various prices within the ranges provided. Detailed information regarding the number of shares sold at each individual price point is available upon request to the SEC, the issuer, or a security holder.
Investors often monitor insider sales as they can provide insights into an executive's perspective on the company's current valuation and future prospects. However, it should be noted that insider transactions may be subject to various personal financial needs or portfolio strategies and may not always indicate a change in company outlook.
The shares of Becton Dickinson & Co, a leading medical technology company known for its medical instruments and apparatus, are publicly traded on the New York Stock Exchange under the ticker symbol BDX.
InvestingPro Insights
Following the recent insider sale by executive Roland Goette, investors in Becton Dickinson & Co (NYSE:BDX) may also find it beneficial to consider key financial metrics and analyst insights provided by InvestingPro. The company, with a robust market capitalization of $68.4 billion, is trading at a price-to-earnings (P/E) ratio of 51.88. While this indicates a high earnings multiple, it's worth noting that the adjusted P/E ratio for the last twelve months as of Q2 2024 is lower at 33.25, suggesting a potential normalization in valuation.
InvestingPro Tips reveal that Becton Dickinson has a notable track record of raising its dividend for 53 consecutive years, indicating a strong commitment to returning value to shareholders. Additionally, despite 12 analysts revising their earnings estimates downwards for the upcoming period, the company is still expected to grow its net income this year. This could signal confidence in the company's ability to navigate through challenges while maintaining profitability.
For investors seeking more comprehensive analysis and additional InvestingPro Tips, there are 10 more tips available for Becton Dickinson on InvestingPro. These tips could further inform investment decisions, especially when considering the company's position as a prominent player in the Healthcare Equipment & Supplies industry and its current trading near the 52-week low. Interested investors can utilize the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes access to these valuable insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.